Moderate-to-severe Atopic Dermatitis Clinical Trials

9 recruitingLast updated: June 17, 2026

There are 9 actively recruiting moderate-to-severe atopic dermatitis clinical trials across 13 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Shenyang, Liaoning, China, Guangzhou, Guangdong, China, Arezzo, Italy. Updated daily from ClinicalTrials.gov.


Moderate-to-severe Atopic Dermatitis Trials at a Glance

9 actively recruiting trials for moderate-to-severe atopic dermatitis are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Shenyang, Guangzhou, and Arezzo. Lead sponsors running moderate-to-severe atopic dermatitis studies include Guangdong Hengrui Pharmaceutical Co., Ltd, Jiangsu vcare pharmaceutical technology co., LTD, and Sitryx Therapeutics Ltd.

Browse moderate-to-severe atopic dermatitis trials by phase

Treatments under study

About Moderate-to-severe Atopic Dermatitis Clinical Trials

Looking for clinical trials for Moderate-to-severe Atopic Dermatitis? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Moderate-to-severe Atopic Dermatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Moderate-to-severe Atopic Dermatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 1

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
TRex Bio, Inc.115 enrolled15 locationsNCT06934252
Recruiting
Phase 1

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Sitryx Therapeutics Ltd149 enrolled14 locationsNCT07558668
Recruiting
Phase 2

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd200 enrolled2 locationsNCT07321951
Recruiting
Phase 2

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd75 enrolled1 locationNCT07211542
Recruiting
Phase 3

A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Adolescents With Moderate-to-severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd201 enrolled2 locationsNCT07309055
Recruiting
Phase 3

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

Moderate-to-severe Atopic Dermatitis
medac GmbH277 enrolled30 locationsNCT06239311
Recruiting
Phase 1Phase 2

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Children and Adolescents With Moderate-to-severe Atopic Dermatitis
Guangdong Hengrui Pharmaceutical Co., Ltd50 enrolled1 locationNCT06713499
Recruiting
Phase 3

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Jiangsu vcare pharmaceutical technology co., LTD480 enrolled1 locationNCT06723080
Recruiting

TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
Technische Universität Dresden2,800 enrolled3 locationsNCT03057860